Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Rectal Neoplasms × dalotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3 Breast Neoplasms 3 Neoplasms 2 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Multiple Myeloma 1 Fallopian Tube Neoplasms 1 Advanced Solid Tumors 1

Interventions

Oxaliplatin 46 Fluorouracil 43 Leucovorin 40 Capecitabine 36 Bevacizumab 28 Irinotecan 27 Radiotherapy 22 Cetuximab 21 Panitumumab 12 Radiation 11 Folfox protocol 10 Surgical Procedures, Operative 9 IFL protocol 7 Radiotherapy, Intensity-Modulated 6 aflibercept 5 Magnetic Resonance Spectroscopy 5 Immunohistochemistry 5 Chemotherapy, Adjuvant 5 Gene Expression Profiling 4 Floxuridine 4 dehydroftorafur 3 XELOX 3 Ramucirumab 3 Neoadjuvant Therapy 3 Fluorodeoxyglucose F18 3 Erlotinib Hydrochloride 3 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3 veliparib 2 trifluridine tipiracil drug combination 2 regorafenib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01609231 2020-05-04

MK-0646-025

Merck Sharp & Dohme LLC

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡